Impact Factor 5.810 | CiteScore 6.2
More on impact ›
The Drugs Outcomes Research and Policies section is devoted to the evaluation of drugs, advanced therapies and medical devices containing drugs in real life conditions, following their approval by regulatory authorities and access to the market. Areas covered by this section include, but are not limited to:
Meta analyses of clinical trials will only be considered for peer-review if the drug is registered and available to be used.
The following studies will not be considered for review in this section, but might be considered in other sections in the journal:
NOTE: The terms drug and medicine are considered synonymous in this text.
Indexed in: Chemical Abstracts Service (CAS), CrossRef, DOAJ, Google Scholar, PubMed, PubMed Central (PMC), Scopus, Web of Science Science Citation Index Expanded (SCIE)
PMCID: all published articles receive a PMCID
Drugs Outcomes Research and Policies welcomes submissions of the following article types: Brief Research Report, Clinical Trial, Correction, Curriculum, Instruction, and Pedagogy, Data Report, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Policy and Practice Reviews, Policy Brief, Review, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Drugs Outcomes Research and Policies, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact email@example.com
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact firstname.lastname@example.org